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Abstract
Background: Pre-existing immunity to Vaccinia Tian Tan virus (VTT) resulting from a large vaccination campaign against
smallpox prior to the early 1980s in China, has been a major issue for application of VTT-vector based vaccines. It is essential
to establish a sensitive and high-throughput neutralization assay to understand the epidemiology of Vaccinia-specific
immunity in current populations in China.
Methodology/Principal Findings: A new anti-Vaccinia virus (VACV) neutralization assay that used the attenuated
replication-competent VTT carrying the firefly luciferase gene of Photinus pyralis (rTV-Fluc) was established and standardized
for critical parameters that included the choice of cell line, viral infection dose, and the infection time. The current study
evaluated the maintenance of virus-specific immunity after smallpox vaccination by conducting a non-randomized, cross-
sectional analysis of antiviral antibody-mediated immune responses in volunteers examined 30–55 years after vaccination.
The rTV-Fluc neutralization assay was able to detect neutralizing antibodies (NAbs) against Vaccinia virus without the ability
to differentiate strains of Vaccinia virus. We showed that the neutralizing titers measured by our assay were similar to those
obtained by the traditional plaque reduction neutralization test (PRNT). Using this assay, we found a low prevalence of NAb
to VTT (7.6%) in individuals born before 1980 from Beijing and Anhui provinces in China, and when present, anti-VTT NAb
titers were low. No NAbs were detected in all 222 samples from individuals born after 1980. There was no significant
difference observed for titer or prevalence by gender, age range and geographic origin.
Conclusion: A simplified, sensitive, standardized, reproducible, and high-throughput assay was developed for the
quantitation of NAbs against different Vaccinia strains. The current study provides useful insights for the future
development of VTT-based vaccination in Beijing and Anhui provinces of China.
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Introduction
Vaccinia Tian Tan virus (VTT) was historically used for the
vaccination of millions of Chinese people during the worldwide
smallpox prevention campaign, and such programs led to the
eradication of Variola in China prior to 1980 [1–4]. In recent
years, VTT has been used as a virus vector for the development of
potential vaccines for Human immunodeficiency virus (HIV),
Hepatitis B virus (HBV), Human papillomavirus (HPV), Influenza
virus subtype H5N1, Aichi virus (AIV), Severe acute respiratory
syndrome coronavirus (SARS-CoV), and Rabies virus that can
confer protection to immunized animals [5–11]. Although these
approaches have been successful in animal models, significant
problems remain for the use of VTT vector in humans. Current
views on Vaccinia virus (VACV) suggest that it’s immunity is high
or existent in the current population born before the early 1980s
[12], which may influence both the titer and duration of the
antibody response induced by a second distinct Vaccinia
recombinant vaccine [13]. Preexisting immunity to viral vectors
has been a major issue for the application of VTT vector-based
vaccines in humans [14]. Therefore, a high-throughput neutral-
ization assay is urgently needed for assessing the level of immunity
to VACV in current populations. Such a neutralization assay
would also be useful to monitor the efficiency of vaccination in
experimental and clinical settings and allows standardization
worldwide.
The conventional method used for determining anti-Vaccinia
neutralizing antibody titer is the plaque reduction neutralization
test (PRNT). The PRNT is considered the ‘‘gold standard’’ of
assays because it is specific, direct, and reproducible [15,16].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33392However, the PRNT is time-consuming and labor-intensive,
which is not applicable for the large-scale screening that is needed
for a population survey. In recent years, there have been several
assays developed that are high-throughput, semi-automated, and
do not rely on plaque formation and manual counts. Some of these
assays detect aggregate cell infection as indicated by enzyme
immunoassay [17] or the expression of recombinant reporter
genes, such as b-galactosidase (b-gal) and green fluorescent protein
(GFP) [18,19]. Perceived difficulties of these assays may include
the use of cell suspension cultures for GFP assays, which may be
laborious to maintain, and a lower dynamic range observed with
enzymatic (BGZ) assays.
Here, we describe the development of a novel neutralization
assay in a 96-well format that uses the replication-competent VTT
possessing a firefly luciferase protein reporter gene (rTV-Fluc).
Upon infection, neutralizing antibody (NAb) activity is evaluated
as a function of the reduction of the Fluc activity in the presence of
specific anti-Vaccinia antibodies in the serum. The use of Fluc in
the neutralization assay has several advantages over other
reporters, such as, chloramphenicol acetyltransferase (CAT), b-
gal, and GFP, including high sensitivity, broad dynamic range,
and simplicity [20]. The sensitivity of chemiluminescence
detection has been reported to be 10-fold greater than a
fluorescence-based assay, and 80- to 100-fold greater than
colorimetric methods [21].
Since people who were vaccinated decades ago with Vaccinia
still maintain some immunity against VTT, future vaccination
using VTT vector-based vaccines might be affected. Thus, it is
important to clarify whether individuals vaccinated decades ago
maintain any immunity to VTT, and if so, what proportion of the
population possesses this immunity and the effectiveness of this
immunity. The current study used the novel rTV-Fluc neutrali-
zation assay to study the prevalence of VTT-specific antibodies
among a representative current Chinese population.
Results
Construction of rTV-Fluc
After approximately 6–10 rounds of purification, insertion of the
Fluc into the VTT genome was confirmed by polymerase chain
reaction (PCR), and expression was detected using the chemilu-
minescence assay. The amplified Fluc product was identified that
exactly matched the published sequence (GenBank accession:
EU921841). The 10 mL rTV-Fluc virus stocks (lot number:
V201135) with a titer of 10
7 plaque-forming units (PFU)/mL were
aliquoted and stored at liquid nitrogen at China Center For Type
Culture Collection, Wuhan, China.
Optimization of conditions for the neutralization assay
Several cell lines were compared for use in the Fluc assay with
different doses of rTV-Fluc virus (Figure 1A and B). Luciferase
expression was detected by incubation with luciferin substrate.
The two cell lines, Vero and 143TK, produced very low
background similar to the control CEF cells (not shown). It was
found that 80% of 143TK cells resulted in cytopathic effect after
infection for 36 h in the high dose group (10
3 PFU/10
4 cells in a
96-well plate). Therefore, the 143TK cell line was not suitable for
this assay due to the high susceptibility to rTV-Fluc infection.
Thus, the Vero cell line was chosen for further experiments
because susceptibility was less than for 143TK cells, and it was
suitable for low-titer NAb detection. Since Vero cells had a slow
growth rate, 10
4 cells/well in a 96-well plate were needed to
produce a monolayer that allowed detection of viral proliferation
following a 2-day incubation. Shorter incubation periods were
examined and a 24 h incubation period was sufficient to
distinguish the luciferase expression of infected cells from the
background level of normal cells, 87.1-fold higher than back-
ground. Moreover, comparison of the addition of 10
4 cells/well
and 3610
4 cells/well in a 96-well plate favored the higher cell
density due to better reproducibility (CV, 3.07% vs 1.75%, at
20 PFU/well; Figure 1C and D). It was found that washing once
with phosphate-buffered saline (PBS) before the addition of the
luciferin substrate did not significantly decrease the luciferase
antigen expression compared with no washing (Figure 1E and F).
Vero cells were infected with different doses of rTV-Fluc to
determine the optimal concentration to be used in the neutrali-
zation assay. Figure 1G depicts the direct correlation between
rTV-Fluc concentration and luciferase transgene expression.
There was a dynamic range of viral infecting dose (22–
1800 PFU/30,000 cells), where the increase in expression was
linearly correlated with the increase in viral infection dose. Next,
the neutralizing activity of a Vaccinia-vaccinated rabbit serum
sample was determined comparing different rTV-Fluc concentra-
tions to evaluate the optimal multiplicity of infection (MOI) of
virus to be used in this assay (Figure 1H). Poor virus neutralization
was observed at PFU/well cell ratios of 40 and 400 with naı ¨ve
rabbit serum. A similar dynamic curve of neutralization infection
was obtained at both 40 PFU/30,000 cells and 400 PFU/
30,000 cells; virus neutralization decreased as serum NAb
concentration decreased. When a lower PFU/well ratio was used,
the correlation decreased with the presence of samples with high
NAb titers to VTT. In this assay, the reference rabbit antiserum
neutralized rTV-Fluc at PFU/well ratios of 40 and 400 with NT50
of 2336 and 3468, respectively (P.0.05). A test serum sample was
assayed three or more times with two concentrations of rTV-Fluc
to confirm the consistency of the assay. An infectious dose of
400 PFU (MOI=0.0133), which is the middle of the linear range,
was chosen as the optimal viral infection dose to perform the assay
due to a lower coefficient of variation (P,0.05). This dose was
determined to be large enough to produce a high signal and thus
permit the evaluation of reduction in transgene expression
following neutralization and was also low enough to render the
assay sensitive. The final format of the rTV-Fluc neutralizing assay
for testing human sera is described in Table 1.
The rTV-Fluc neutralization assay was able to detect
NAbs in rabbit, mouse, and human sera
BALB/c mice were vaccinated twice with recombinant rTV-
HIVgp 145 vaccine, containing the env gene from B’/C recom-
binant HIV-1 S939, and at three weeks after the second
administration, sera were collected and analyzed using the rTV-
Fluc neutralization assay (Figure 2A). Neutralizing activity was
detected for sera from two vaccinated mice (50% neutralization
titer (NT50) of 126 and 583), while the two naı ¨ve mouse sera
showed no significant neutralizing activity. No significant
neutralizing activity was observed for the naı ¨ve rabbit serum;
however, rabbit serum collected at two weeks after the second
VTT inoculation was able to neutralize rTV-Fluc with an NT50 of
3468 (Figure 2B). Finally, sera obtained from two humans
immunized with an experimental HIV vaccinia vaccine (recom-
binant modified vaccinia Ankara, rMVA-HIVgpe) from the
Guangxi Center for Disease Control (CDC) were used to detect
neutralizing activity against the heterologous rTV-Fluc virus
(NT50 of 98 and 226) and no detectable neutralizing activity was
shown in two naı ¨ve human sera (Figure 2C). An additional
27 rMVA-HIVgpe immunized individuals’ sera were analyzed for
neutralizing antibodies. As shown in Figure 2D, the peak levels of
specific anti-MVA NAbs were detected as early as two weeks after
Antibody Detection Assay for Vaccinia
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vaccinees after three months. Taken together, these data showed
that homologous and heterologous anti-VACV NAbs from various
species could be detected using the developed assay.
Comparison of Fluc and PRNT Vaccinia-specific
neutralization assays
As part of the characterization of the new Vaccinia neutrali-
zation assay, it was important to compare the data obtained with
those generated by PRNT. Serum titers obtained by transgene
expression inhibition and replication inhibition with plaque
scoring were compared. Maximum virus infection was observed
in control wells without serum; VTT-antibody positive (reference)
serum and FBS alone were included as positive and negative
controls, respectively. Comparison of titers revealed that NAb
titers of 20:human and 14:rTV-HIVgp:145 immunized mouse
sera in the Fluc assay were higher than for the PRNT assay
(P=0.12) (Figure 3A). Moreover, two serum samples (V1-2 and
Figure 1. The optimization of the rTV-Fluc neutralization assay. (A-B) Several cell lines were compared for use in the luciferase assay. The x-
axis indicates hours after rTV-Fluc infection, added to 10 PFU/30,000 cells (A) and 10
3 PFU/30,000 cells (B) in a 96-well plate. The dotted line
represents the background level of three cell lines. (C–D) The determination of Vero cell density. The x-axis indicates rTV-Fluc input, added to
10
4 cells/well (C) and 3610
4 cells/well (D) in a 96-well plate. The dot shows the luciferase transgene expression after 24 h incubation. (E–F) The
influence of washing with PBS before the addition of luciferin substrate. The x-axis indicates rTV-Fluc input, and the dot represents the luciferase
transgene expression after 24 h incubation with no washing (E) and washing (F). (G) Dose-response between rTV-Fluc input and luciferase transgene
expression. The x-axis indicates virus concentration, ranging from 0.8–5400 PFU/well, added to 3610
4 cells/well in a 96-well plate. Each data point
represents the average of eight experiments. (H) Two different concentrations of rTV-Fluc (N,m, 400 PFU/well; &,., 40 PFU/well) were used with
various concentrations of rabbit serum for neutralizing activity. The same experiment was carried out with rabbit sera collected before (m,.) and two
weeks after (N,&) vaccination with VTT. Each data point represents the average of three experiments.
doi:10.1371/journal.pone.0033392.g001
Table 1. Description of the final format of the luciferase neutralization assay for human sera.
Step Description
Viral neutralization, infection of cells and replication
Samples collection Collection of blood sample by venipuncture. Inactivation of separated sera at 56uC for 30 min.
Dilution of sera Preparation of seven 3-fold dilution steps in a flat-bottom 96-well plate in a final volume of 100 ul. Preparation
of 150 ml medium for non-neutralized virus control. A control serum with established NT titer should be
included in each assay plate as a standard.
Administration of virus and neutralization Dispensing of 50 ml containing 400 pfu of VTT to each well. Incubation at 37uC, 5% CO2 for 1 h.
Addition of cells and viral replication Addition of 100 ml containing 30,000 Vero cells to each well. Incubation at 37uC, 5% CO2 for 24 h.
Luciferase assay
Addition of substrate Aspiration of 100 ml supernatant. Addition of 100 ml/well of Bright-Glo
TM luciferin equilibrated to room
temperature. Incubation at room temperature (20uC) for 2 min, keeping from light.
Measurement of luminescence Measuring luminescence with the GLOMAXTM 96 microplate luminometer.
doi:10.1371/journal.pone.0033392.t001
Antibody Detection Assay for Vaccinia
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33392V2-1), negative for NAb titer in PRNT, were determined to be
positive by the Fluc assay (NT50 of 35 and 47). Analysis of the data
using the t-test (Figure 3B) indicated that under the experimental
conditions developed, a high correlation existed between the two
methods (r=0.93, P,0.0001). Thus, we established that the newly
developed luciferase reporter-gene assay was more rapid (24:h)
and as sensitive as the traditional PRNT.
Applications of the Fluc neutralization assay in screening
of human samples from China
One of the important applications of the developed assay was its
use to investigate the seroprevalence of preexisting VTT NAbs in
the general population. NAb titer was determined by the Fluc
assay in three different age-related cohorts that covered the period
from before 1970 to after the cessation of routine smallpox
vaccination in China in 1980. As shown in Table 2, all 222 sera
from individuals born after 1980 were determined to be negative
for anti-VTT NAb titers. The overall percentage of people with
positive anti-VTT NAb (titer .30) was 7.6% in individuals born
before 1980 (21/278). The percentage of positive VTT NAbs
(NT50 of .30) and individuals with high titer of anti-VTT
antibodies (NT50 of .100) increased with age. Of the 31–40 and
41–56 age groups as of 2011, 5.5% and 10.3%, respectively, had
evidence of VTT-specific NAbs. There was no significant
difference (P.0.05) between the two cohorts in the seropositivity
rate determined.
Taken together, these data showed that the developed assay was
sensitive enough to detect even low levels of viral inhibition (NT50
of 30–100), and most neutralization titers detected in 21 seropos-
itive samples were in this range (Table 2). Interestingly, it was
found that even .40 years post-vaccination, one individual
maintained a high level of Vaccinia-specific NAbs, with a titer
similar to that obtained with the anti-VTT rabbit sera (ATRS)
(NT50 of 1810 vs 3468). There was no statistically significant
association observed between gender and the presence of
antibodies against VTT (P.0.05). We further analyzed the
samples collected from various locations, including Beijing and
Anhui provinces, and found no significant difference in the
seropositivity rate of NAbs.
Discussion
In this study, we established a novel VACV-neutralization assay
to replace the PRNT, which was based on inhibiting the infection
of Vero cells by a recombinant VTT that carried a firefly luciferase
gene with the resulting inhibition of the transgene expression. The
quantitative analysis using the assay was supported by data that
showed the number of rTV-Fluc particles bound to cells was
directly proportional to transgene expression [22]. The use of Fluc
as a reporter offers several advantages compared to the standard
PRNT as follows: (i) higher resolution available due to the precise
measurement of firefly luciferase transgene expression and the
amplification effect of chemiluminescence; (ii) greater reliability
since the data gathering step of the rTV-Fluc assay is automated;
(iii) shorter overall assay time due to a reduction in incubation time
(24 h vs. 4–6 d) [15,16]; (iv) higher throughput via the 96-well
format versus 6-well in PRNT; (v) five-fold reduction in the
volume of valuable sera needed for analysis. Recombinant VACV
expressing other reporter genes, such as GFP and b-gal, may also
be useful for establishing high-throughput, sensitive neutralization
assays. Sprangers et al. (2003) compared luciferase activity to the
automated quantitation of GFP and b-gal protein expression in
determining anti-Ad5 NAb, and found that luciferase activity
detection was more sensitive than other transgene systems and
required fewer target cells, which made it suitable for use in 384-
well plates for high-throughput [20]. Hatakeyama et al. (2005)
noted only moderately positive correlation between antibodies
detected by the PRNT assay and those by ELISA among
representatives of Japanese population, which was due to a
number of epitopes on the viral proteins other than neutralizing
epitopes on Vaccinia virus [23].
The current study examined the importance of the standard-
ization of critical parameters including the choice of cell line, viral
infection dose, incubation time, and washing steps that could affect
the sensitivity, reproducibility, specificity, and correlation with the
PRNT assay. Adequate control of these parameters reduces
variability in titer values and allows reliable comparison of data
from different studies [22]. Cells were chosen based on their ability
to allow rTV-Fluc replication and to not produce cytopathic effect
(CPE) following a 24–48 h incubation. Two cell lines (Vero and
143TK) and primary chicken embryo fibroblasts (CEF) were
tested for compatibility with the rTV-Fluc assay. Of the three,
Vero cells allowed viral replication after 24 h without visible CPE,
and the results obtained with Vero cells were reproducible. The
determination of optimal viral concentration is important because
the infectious dose must be low in order to increase assay
sensitivity. However, the infecting dose should also be high enough
Figure 2. Neutralizing antibodies in mouse, rabbit, and human
serum samples. (A) Sera from two rTV-HIVgp 145-vaccinated mice
(&, m) and two naı ¨ve mice (%,g). (B) An anti-VTT rabbit serum (&),
together with an unrelated rabbit control serum (%). (C) Sera from two
rMVA-HIVgpe-vaccinated human (&, m) and two naı ¨ve human (%, g)
were tested using the rTV-Fluc neutralization assay. The x-axis indicates
serial dilutions of sera, ranging from 1:30 to 1:21870. (D) The dynamics
of anti-rMVA-HIVgpe antibody titers. Two months after the first survey
at 15 days after immunization, anti-rMVA-HIVgpe antibody titers of 27
participants were measured again. The x-axis indicates months after
immunization. The y-axis indicates the MVA specific neutralization
antibody titers. The dotted line represents the detection limit of the
assay. Each data point in A-D represents the average of three
experiments.
doi:10.1371/journal.pone.0033392.g002
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to neutralization.
In this assay, the dynamic range was found to be 22–
1800 PFU/30,000 cells. We determined that 400 PFU (MOI=
0.0133), which was in the middle of the linear range, was
appropriate for both reproducibility and sensitivity. The linear
correlation obtained between the Vaccinia vector concentration
and transgene Fluc expression supports the hypothesis of one
virion-one transduction event [24]. It was found that sera from
three different species had different levels of nonspecific inhibition
effect at 1:30 dilution. In this assay, the samples were considered
positive only when the inhibition percentage reached 50%. In fact,
all naı ¨ve samples at the starting dilution (1:30) were determined to
be negative although their inhibition percentage ranged from 20–
40%. Thus, an inhibition percentage ,50% will not affect the
results of detection. It was found that the nonspecific inhibition
effect decreased as serum dilution increased from 30 folds. So, we
determined that the nonspecific neutralization effect could be
ignored when the serum dilution was more than 30 folds.
In order to test the rTV-Fluc assay, 20 sera from healthy human
individuals born before 1980, and 14 rTV-HIVgp 145 immunized
mouse sera at two weeks after second immunization were tested.
Comparison of the neutralization titers obtained by rTV-Fluc to
those by PRNT indicated a high correlation (r=0.93). Moreover,
statistical comparisons indicated that the limit of detection of rTV-
Fluc assay was lower than that of the PRNT assay. We believed
that the slightly enhanced sensitivity observed was due to
differences in the protocols followed. For both assays, the virus
was incubated with antibody for 1 h, however, in the rTV-Fluc
assay the virus-antibody suspension was only diluted two-fold
when the cells were added and was not removed from the
Figure 3. Comparison of two different neutralization assays for the presence of NAbs against VTT in human sera. Serum titers were
determined by the dilution at which 50% of plaque viability or luciferase expression was observed. (A) The y-axis indicates the serum dilution at
which 50% infection inhibition was observed, relative to the maximum control value. Dotted lines indicate the lower limits of detection as defined by
the maximum concentration of serum. NC1 to NA10, human samples; V1-1 to V6-4, mouse samples. (B) Correlation between neutralization titers
obtained in luciferase (y-axis) and PRNT (x-axis). Notably, the overstriking point in B represented the 23:sera with negative titers. Each data point and
column represented the average of three experiments.
doi:10.1371/journal.pone.0033392.g003
Table 2. Epidemiological study of neutralizing antibodies in
the general population in China.
VTT NAb titer
a, num (%) Total num (%)
,30 (Neg) 30–100 .100 .30 (Pos)
Age, years Num
18–30 222 222 (100%) 0 (0%) 0 (0%) 0 (0%)
31–40 162 153 (94.5%) 8 (4.9%) 1 (0.6%) 9 (5.5%)
41–56 116 104 (89.7%) 10 (8.6%) 2 (1.7%) 12 (10.3%)
b
Total 500 479 (95.8%) 18 (3.6%) 3 (0.6%) 21 (4.2%)
Sex
Male 278 266 (95.7%) 10 (3.6%) 2 (0.7%) 12 (4.3%)
Female 222 213 (96.0%) 8 (3.6%) 1 (0.4%) 9 (4.0%)
Total 500 479 (95.8%) 18 (3.6%) 3 (0.6%) 21 (4.2%)
Site
Beijing 300 290 (96.6%) 8 (2.7%) 2 (0.7%) 10 (3.3%)
Anhui 200 189 (94.5%) 10 (5.0%) 1 (0.5%) 11 (5.5%)
Total 500 479 (95.8%) 18 (3.6%) 3 (0.6%) 21 (4.2%)
aThe titers (vaccinia-neutralizing activity) were determined using the
neutralization assay described in Table 1. Arbitrary intervals were established
as a qualitative reference for the potency of a determined serum, i.e., negative
(,30), low (30–100), and high (.100).
bthe percentage of positive VTT NAbs increased with age.
doi:10.1371/journal.pone.0033392.t002
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incubation in the PRNT, when the liquid medium was replaced
with a semi-solid overlay in order to obtain discrete plaques.
Neutralization of VACV could occur even after the virus had
attached to cells [25], and hence, the new method described here
was sensitive enough to detect both high-titer and low-titer NAbs
in mouse, rabbit, and human serum samples, and should provide
simple validation and transfer to other laboratories.
The present study investigated the utility of the rTV-Fluc
neutralization assays in two different studies. In the first study, the
assay was used to perform an epidemiological study to ensure that
VTT was the optimal vaccine vector for application in the Chinese
populations. There were concerns that the utility of recombinant
VACV vector-based vaccines could be limited by the high
prevalence of pre-existing VACV NAbs in human populations
[13]. Now, live-virus vector-based vaccination strategies are likely
to increasingly use VACV-derived vectors in future clinical trials
[26–33]. Indeed, VTT was successfully used as virus vector for the
development of HIV, HBV, HPV, H5N1 AIV, SARS-CoV, and
Rabies virus vaccines, conferring protection to immunized animals
[5–11]. However, significant problems remain for the use of VTT
vectors in humans, such as preexisting immunity to viral vectors.
The pre-existing immunity of the vaccinee against the viral vector
is likely to limit the amount of virus that can reach and infect the
target tissue, thus, decreasing the expression of the virus encoded
foreign antigen, and consequently the immune response generated
against the target antigen [13,34].
It is known that the Orthopoxvirus serological tests, such as
ELISA, PRNT, are not virus species specific due to the high level
of cross-antigenicity observed among the species of the OPXV
genus. In this study, the specificity of rTV-Fluc assay was not
analyzed with other orthopoxvirus. However, we determined that
the antibodies detected with developed assay most likely had been
induced during smallpox eradication campaign by VTT, since no
other strain had been used for vaccination against smallpox in
China. To our knowledge, this was the first study of the prevalence
and potency of VTT-specific NAb in human samples from
different geographic origin in China. The serologic survey was
performed using a diverse population (60% in Beijing, others in
Anhui) with a male-to-female ratio of 1:1, comprising a wide range
of ages (18–56 years of age as of 2011). Only a low prevalence of
NAb to VTT (7.6%) was seen in Chinese people born before 1980,
mostly at low titers, and these results did not corroborate
immunological studies and VACV specific antibodies population
screenings that indicated anti-VACV NAb were low and stable in
vaccinees for up to 30–70 years post-vaccination [12,35,36]. In
Japan, Shuji Hatakeyama et al. [23] reported that approximately
80% of people born before 1969 and 50% of those born between
1969 and 1975 were also found to have maintained NAb against
VACV.
Interestingly, we also found that the percentage of positive VTT
NAbs (titers .30) in China increased with age. We believed that
this may be due to the different number of smallpox vaccinations
participants had received. The prevalence of pre-existing NAb to
VTT could guide the future administration of VTT vector-based
products in Beijing and Anhui provinces.
Since the kinetics of immunity to foreign antigen seemed to
parallel the kinetics to vector [37], the second part of the study
focused on the evaluation of the dynamics of anti-VACV NAb
titers generated upon the administration of recombinant MVA
vector-based vaccines in humans. The rTV-Fluc neutralization
assay described here was able to detect the specific humoral
responses elicited by the MVA vectors in a time- and dose-
dependent manner. Although the duration of NAbs with multiple
MVA vector vaccination was not analyzed in present study, it was
believed that the stronger and long-lasting immunity could be
achieved by the prime-boost strategy in the current Chinese
population, as indicated by Lai L et al. [38].
Amanna et al. [39] reviewed that the smallpox vaccine-induced
antibody responses were both necessary and sufficient for
protection against lethal monkeypox infection. At present, the
duration of Vaccinia-specific NAbs is controversial. Some studies
have demonstrated that full protective immunity conferred by
smallpox vaccination lasted only 3–5 years and that even partial
immunity faded substantially after 10–20 years [40–42]. Mean-
while, others have shown that immunity to smallpox may still be
present many years after vaccination [23,35,43]. Several studies
have shown that serum neutralizing antibody titers .32 were
associated with protective immunity against smallpox disease
[16,42,44,45]. Using this level of NAb as a marker for smallpox
resistance, we determined that only 7.6% of the subjects born
before 1980 in China demonstrated titers above this level. We do
not believe that the low prevalence of VTT NAb was due to low
sensitivity of our assay. The sensitivity of rTV-Fluc assay was
similar and even slightly higher to the PRNT. Until now, there has
been no other report on the epidemiological study of VACV-
specific NAbs in the general population of China. Therefore, it
was unknown whether this limited study population was truly
representative of national level of antibody titers. This will be the
focus of future studies. These data suggested that people born after
the early 1980s, when China stopped vaccinating against
smallpox, would be vulnerable to smallpox, and the vaccinated
older population would also be vulnerable due to low NAb titers.
Some previous findings had indicated that human memory B cells
could be maintained for life in the absence of antigenic re-
exposure [39]. Although the VACV NAbs in this study declined to
undetectable levels in most populations studied in China, we
believed that VACV-specific memory B cells could be activated to
rapidly produce neutralizing antibodies upon reimmunization.
Therefore, VACV and the recombinant VACV vector-based
vaccines should attract more attention for their use as a vaccine
against Variola virus in China, due to the rise in bio-terrorism
threats around the world [46]. In the event of an Orthopoxvirus
outbreak, the speed and high-throughput nature of the rTV-Fluc
assay may prove extremely valuable.
In summary, a simple, objective, reproducible, time- and labor-
saving chemiluminescence-based neutralization assay was devel-
oped for the determination of anti-VACV NAbs titers for both
human and animal sera. This new assay may be a good candidate
method for not only performing epidemiologic surveys but also for
monitoring the anti-VACV immune responses in large-scale
clinical trials. Moreover, the assay could also be used in basic
research since it gives a direct measurement of neutralizing
activity.
Methods
Ethics issues
The ethics issues in the study was inspected and approved by
Ethical Committee of Beijing Blood Center. Each participant was
informed of the purpose of the study and written consent was also
obtained from each participant involved in this study.
Cells and virus
Vero (ATCC, CCL81) and 143TK (CCTCC, GDC076) cells
were used for the Fluc neutralizing assay, grown at 37uC under
5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 1% L-
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amino acids (HyClone, South Logan, UT, USA). Primary chicken
embryo fibroblasts (CEF) prepared from 9-day-old embryos were
grown in DMEM supplemented with 10% FBS. The original
VTT strain was derived in our institute. VTT was propagated in
CEF cell, and the titer was determined by a plaque-forming assay
using crystal violet staining and primary CEF [1].
Vaccinia virus antisera
For experiments using the VTT, sera from mice and rabbits
vaccinated with VTT and control normal mouse and rabbit sera
were used. The anti-VTT rabbit sera (ATRS) was kindly provided
by Dr. Huanyu An (Beijing Tiantan Biological Products, Beijing,
China). Samples from recombinant MVA-HIVgpe virus-vaccinat-
ed participants were kindly provided by Dr. Wei Kong (Jilin
University, Changchun, China).
Normal human serum samples
Serum samples from 278 donors (169 males, 109 females)
ranging in age from 31–56 years as of 2011 were obtained from
a diverse human population of healthy individuals in Beijing and
Anhui province, China, with a known history of smallpox
vaccination. Negative controls included 222 serum samples that
had been obtained from unvaccinated people (109 male, 113 fe-
male) born after 1980 (18–31 years, as of 2011) to evaluate the
specific NAbs against VTT since routine smallpox vaccination was
discontinued in China in 1980. The samples from healthy
participants were collected from the Beijing (300 samples) and
Anhui province (200 samples). All samples were frozen at –80uC
and banked at the various institutions after collection. Samples
were shipped in dry ice to our department in the National
Institutes for Food and Drug Control. All samples were thawed,
aliquoted, and stored at –80uC. All samples in our study were
subjected to identical treatment and storage conditions and were
considered of equivalent quality.
Construction of rTV-Fluc
PCR was used to construct recombinant shuttle plasmid
pSCFluc [28,47]. Briefly, the firefly luciferase gene of Photinus
pyralis was from pLUCF (kindly provided by John T. Schiller,
National Cancer Institute, Bethesda, MD, USA) and inserted into
the SalI-SmaI site of pSC65 transfer vector (kindly provided by B.
Moss, NIAID, NIH, USA), under the control of the VACV-
specific early/late promoter, and adjacent to the gene that encodes
lacZ expressed as a screening marker for recombination, which was
regulated by the VACV P7.5 late promoter. Primers were
designed with the inclusion of restriction enzyme sites for SalI or
SmaI. The two primers used for this test were: 5’-GTCGACGC-
CACCATGGAAGATGCCAAAAAC-3’ (sense, SalI site under-
lined) and 5’-CCCGGGTTACACGGCGATCTTGCCGCCC-3’
(antisense, SmaI site underlined). The amplification cycles were
94uC for 2 min followed by 35 cycles of 94uC for 30 s, 55uC for
30 s and 72uC for 2 min plus the last extension of 72uC for
10 min. Amplified PCR products were purified using a QIAquick
PCR purification kit (QIAGEN, Valencia, CA, USA) and were
subjected to direct DNA sequencing using an automated ABI
377 DNA sequencer (Applied Biosystems, Foster City, CA, USA).
The rTV-Fluc virus was generated in CEF cells using a
homologous recombination method [48]. CEF cells were infected
with VTT at multiplicity of infection (MOI) of 0.01 and
subsequently transfected with the shuttle vector, pSCFluc,
designed to recombine specifically with the TK gene of the
VTT to obtain rTV-Fluc recombinant viruses, which were
selected by blue/white plaque screening. The rTV-Fluc virus
was propagated, purified, and titrated in primary CEF, as
previously described [48].
Firefly luciferase-based vaccinia neutralization assay (Fluc
assay)
Neutralization was measured by the reduction in Fluc reporter
gene expression of rTV-Fluc inhibited by Vaccinia NAb present in
serum samples. During the development stages of the assay, the
following parameters were tested: cell lines, incubation time, cell
density, washing with PBS, and virus concentration. Different cell
lines (Vero and 142TK) and primary CEF were screened to
determine the infection profiles of the rTV-Fluc virus. All cells
were added as a trypsinized single-cell suspension. Viral progeny
were allowed to grow in the cells for up to 48 h after infection.
Cells density was tested with 10
4 and 3610
4 cells/well in a 96-well
flat-bottom culture plate (Corning-Costar, Tokyo, Japan). The
influence of washing once with PBS on luciferase quantitation was
tested with serial titers of rTV-Fluc virus. In determining the
optimal viral dose for the assay, we considered both the natural
infectivity of the virus in Vero cells and the variability of infection
in the presence of varying dilutions of serum containing vaccinia
NAb involving 0.8, 2, 7, 22, 66, 200, 600, 1800, and 5400 PFU/
50 mL of diluted virus and nine dilutions of anti-VTT rabbit
serum. Diluted serum (100 mL) was distributed into each of three
corresponding wells in a 96-well plate and 50 mL of rTV-Fluc virus
was added to each well and the plates were incubated at 37uC, 5%
CO2 for 1 h. Following incubation, 100 mL of cells was added to
each well. Plates were placed on a plate shaker for 1 min and
incubated at 37uC, 5% CO2 for up to 48 h. After incubation,
100 mL of supernatant was aspirated and 100 mL of D-luciferin
substrate (Caliper, Hopkinton, MA, USA) was added into each
well protected from light at room temperature for 2 min, after
which luminescence was measured using a GLOMAX 96
microplate luminometer (Promega, Madison, WI, USA). An
anti-VTT rabbit serum (ATRS) was used as reference to establish
an in-house standard serum sample, whereas pooled serum
samples from Vaccinia-naı ¨ve individuals, pre-immune animal
serum samples, and FBS were used as negative controls. The 50%
neutralization titer (NT50) for each serum sample was defined as
the serum dilution at which the relative light unit (RLU) was
reduced by 50% compared with virus-containing control wells
after subtraction of the background RLU in cell-containing control
wells. Titers of .30 were considered positive.
Plaque reduction neutralization test (PRNT)
The traditional control neutralization assay was performed
according to an optimized protocol similar to that previously
described [23]. Sera were serially diluted to five five-fold dilutions
at the range from 1:40 to 1:25000, depending on the expected
titer. Tubes containing 550 mL of each dilution and an equal
volume of rTV-Fluc virus (400 PFU/mL) were mixed. After
incubation at 37uC, 5% CO2 for 1 h, 500 mL was added to Vero
cells, in duplicate, and plates were incubated for 2 h at 37uC, 5%
CO2 with intermittent rocking, followed by the addition of 3 mL of
overlay medium containing 0.5% agarose. On day 4, viral plaques
were visualized by staining with 0.1% crystal violet in PBS
containing 0.2% formaldehyde and counted. The NT50 was
defined as the reciprocal of the serum dilution required for 50%
reduction in rTV-Fluc plaques.
Statistical analysis
The neutralization titers of sera tested by both PRNT and
luciferase were compared. The variance between average titers
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calculated using Student’s t-test. Comparisons between the VTT
seroprevalence in different groups were evaluated using Chi-
square test, and statistical analyses were computed with GraphPad
Prism 5.0 (GraphPad Software, San Diego, CA). For all analyses,
P,0.05 was considered significant.
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